Want to see NTLA full AI Analyst Report?
Intellia Therapeutics (NTLA) Stock Statistics & Valuation Metrics
Total Valuation
Intellia Therapeutics has a market cap or net worth of $1.75B. The enterprise value is $1.89B.
- Market Cap
- $1.75B
- Enterprise Value
- $1.89B
Share Statistics
Intellia Therapeutics has 140,126,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 140,126,700
- Owned by Insiders
- 1.84%
- Owned by Institutions
- 3.78%
Financial Efficiency
Intellia Therapeutics’s return on equity (ROE) is -0.61 and return on invested capital (ROIC) is -57.67%.
- Return on Equity (ROE)
- -0.61
- Return on Assets (ROA)
- -0.49
- Return on Invested Capital (ROIC)
- -57.67%
- Return on Capital Employed (ROCE)
- -0.60
- Revenue Per Employee
- 179.50K
- Profits Per Employee
- -1.09M
- Employee Count
- 377
- Asset Turnover
- 0.08
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Intellia Therapeutics is -3.71. Intellia Therapeutics’s PEG ratio is -0.10.
- PE Ratio
- -3.71
- PS Ratio
- 29.36
- PB Ratio
- 2.29
- Price to FCF
- -5.01
- Price to Operating Cash Flow
- -4.80
- PEG Ratio
- -0.10
Income Statement
In the last 12 months, Intellia Therapeutics had revenue of 67.67M and earned -412.69M in profits. Earnings per share was -3.81.
- Revenue
- 67.67M
- Gross Profit
- 51.75M
- Operating Income
- -440.99M
- Pretax Income
- -412.69M
- Net Income
- -412.69M
- EBITDA
- -396.77M
- Earnings Per Share (EPS)
- -3.81
Cash Flow
In the last 12 months, operating cash flow was -346.64M and capital expenditures -2.04M, giving a free cash flow of -348.69M billion.
- Operating Cash Flow
- -346.64M
- Free Cash Flow
- -348.69M
- Free Cash Flow per Share
- -2.61
Dividends & Yields
Intellia Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -19.95%
- Earnings Yield
- -24.03%
Stock Price Statistics
- Beta
- 1.97
- 52-Week Price Change
- 1.67%
- 50-Day Moving Average
- 12.24
- 200-Day Moving Average
- 13.11
- Relative Strength Index (RSI)
- 53.44
- Average Volume (3m)
- 4.39M
Important Dates
Intellia Therapeutics upcoming earnings date is Nov 05, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 06, 2026
- Next Earnings Date
- Nov 05, 2026
- Ex-Dividend Date
- ―
Financial Position
Intellia Therapeutics as a current ratio of 5.08, with Debt / Equity ratio of 13.90%
- Current Ratio
- 5.08
- Quick Ratio
- 5.08
- Debt to Market Cap
- 0.07
- Net Debt to EBITDA
- 0.16
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Intellia Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Intellia Therapeutics EV to EBITDA ratio is -4.39, with an EV/FCF ratio of -4.92.
- EV to Sales
- 28.81
- EV to EBITDA
- -4.39
- EV to Free Cash Flow
- -4.92
- EV to Operating Cash Flow
- -4.95
Balance Sheet
Intellia Therapeutics has $437.76M in cash and marketable securities with $73.41M in debt, giving a net cash position of $364.35M billion.
- Cash & Marketable Securities
- $437.76M
- Total Debt
- $73.41M
- Net Cash
- $364.35M
- Net Cash Per Share
- $2.60
- Tangible Book Value Per Share
- $5.45
Margins
Gross margin is -46.48%, with operating margin of -711.66%, and net profit margin of -672.16%.
- Gross Margin
- -46.48%
- Operating Margin
- -711.66%
- Pretax Margin
- -672.16%
- Net Profit Margin
- -672.16%
- EBITDA Margin
- -656.03%
- EBIT Margin
- -672.16%
Analyst Forecast
The average price target for Intellia Therapeutics is $19.91, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $19.91
- Price Target Upside
- 59.66% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 13
- Revenue Growth Forecast
- 12.58%
- EPS Growth Forecast
- 28.42%
Scores
- Smart Score
- 7
- AI Score
- 58